{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "Amount",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "pubchem:7009610",
      "entity_text" : "MD",
      "entity_type" : "simple_chemical"
    },
    "hypothesis_information" : false,
    "context" : {
      "Species" : [ "taxonomy:9606" ]
    }
  },
  "verbose_text" : "The lower level of MD HTA activity identified in this later survey can be explained by the sample of HTA agencies which mainly consisted of drug specific HTA agencies (e.g., Pharmaceutical Benefits Advisory Committee (PBAC) in Australia, Pharmaceutical Management Agency (PHARMAC) in New Zealand, The Dental and Pharmaceutical Benefits Agency (TLV) in Sweden).",
  "reading_complete" : "2020-07-28T16:16:17Z",
  "reader_type" : "machine",
  "reading_started" : "2020-07-28T16:14:08Z",
  "trigger" : "level",
  "evidence" : [ "level of MD" ],
  "pmc_id" : "4535322",
  "score" : 0
}